ScinoPharm Taiwan Ltd
TWSE:1789
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ScinoPharm Taiwan Ltd
Cash from Operating Activities
ScinoPharm Taiwan Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Cash from Operating Activities
NT$595.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Cash from Operating Activities
NT$1.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Cash from Operating Activities
NT$1.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Cash from Operating Activities
NT$7.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
31%
|
CAGR 10-Years
21%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Cash from Operating Activities
NT$1.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
Cash from Operating Activities
-NT$425.9m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Cash from Operating Activities?
Cash from Operating Activities
595.9m
TWD
Based on the financial report for Dec 31, 2025, ScinoPharm Taiwan Ltd's Cash from Operating Activities amounts to 595.9m TWD.
What is ScinoPharm Taiwan Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-5%
Over the last year, the Cash from Operating Activities growth was -21%. The average annual Cash from Operating Activities growth rates for ScinoPharm Taiwan Ltd have been -8% over the past three years , -9% over the past five years , and -5% over the past ten years .
